Abstract: Aim: To review the epidemiology
Uptake of the meningococcal C conjugate vaccine through routine infant vaccination is high. Coverage for 24-month olds has remained at over 90% since first calculated for NSW in 2006.
2 Data on the uptake of the general practitionerbased catch-up program is not available. A NSW Health evaluation of the school-based catch-up program in [2003] [2004] indicated that 76% of high school students and 76% of primary school students were vaccinated (unpublished data).
In addition to the serogroup C conjugate vaccine, quadrivalent meningococcal conjugate and polysaccharide vaccines against serogroups A, C, W135 and Y are available but are not recommended for routine use. A single dose of a quadrivalent meningococcal conjugate vaccine is recommended for people in certain situations, such as travellers who intend visiting areas where epidemics of serogroup A, W135 or Y disease are frequent (e.g. sub-Saharan Africa), for pilgrims to the Hajj in Saudi Arabia, and for laboratory workers who frequently handle N. meningitidis. The vaccines are also recommended for close contacts of cases with disease caused by serogroup A, W135 or Y and for people with high-risk medical conditions.
3 Quadrivalent meningococcal conjugate vaccines are preferred to polysaccharide meningococcal vaccines due to their greater duration of induced immunity. 4 The epidemiology of IMD notifications in NSW for the period 1991-2002 has been reported previously. 5, 6 To explore changes in IMD epidemiology, particularly in relation to the introduction of the serogroup C vaccination program in 2003, this report presents an overview of the epidemiology of IMD in NSW for the period 1991-2011, and presents new data for the period 2003-2011. 
Methods

Results
Trends in IMD notifications, 1991-2011
There was a sustained increase in annual notification rates in the period 1991-2000, followed by a sustained decrease in the period 2000-2011. The notification rate decreased by 74% from a peak of 3.8 per 100 000 population in 2000 
PROBABLE CASE
A probable case requires clinical evidence only.
Clinical evidence (for a probable case)
A probable case requires: Table 2 .
The highest rates of IMD occurred among children aged less than 5 years of age, who accounted for 33.5% of notifications (8.5 per 100 000 population). Within this group, children aged under 12 months were at highest risk (17.9 notifications per 100 000 population). A second smaller peak in the notification rate was seen in the 15-19 and 20-24-year age groups (3.6 and 2.3 notifications per 100 000 population, respectively). The age distribution of cases is similar to the previous study period.
Deaths
In the period 1991-2011, whether the person with IMD died was recorded for 55% of notifications; cases with missing information regarding death were assumed not to have died. There were 181 notified deaths due to IMD in the period, which represents 5.8% of cases. Since 1991, annual case fatality rates have fluctuated between 2.3% and 10.6% (Table 1 ). In the period 2003-2011, there were 54 notified deaths due to IMD, which represents 5.4% of notifications for this period ( Table 2 ). The proportion of cases who died was significantly higher for serogroup C compared to serogroup B disease (RR 2.1, 95% CI 1.1-3.9), for cases presenting with septicaemia compared to meningitis (RR 5.9, 95% CI 2.2-16.4), and for cases aged 45 years and over compared to younger cases (RR 3.0, 95% CI 1.7-5.0). There was no significant association between death and gender. These patterns are similar to those observed in the previous study period. In the same period, the proportion of serotyped cases that were serogroup B increased from 64.4% to 80.4%, and other serogroups from 2.5% to 15.7%.
Serogroup C disease
The decline in serogroup C disease has occurred across all age groups. Immediately after the introduction of the Similarly, the proportion of serotyped cases that are serogroup C has decreased over time across all age groups. This decrease is most marked for 1-19-year olds, but is apparent even in unvaccinated children less than 12 months of age (Figure 2 ). Across the entire study period, the proportion of serotyped notifications that are serogroup C was lower in children under 12 months of age than for the older age groups. The epidemiology of IMD at a national level has been described elsewhere. [7] [8] [9] Nationally, notification rates for IMD have decreased from 3.1 per 100 000 population in 2002 to 1.1 per 100 000 population in 2011. 10 The dramatic reduction in rates of notifications of serogroup C disease in NSW between 2002 and 2011 is comparable to rates observed nationally 8 and in other countries where meningococcal C vaccination programs have been introduced. [11] [12] [13] [14] NSW, Australian and international data consistently indicate there has been no evidence of serogroup replacement following mass meningococcal C immunisation programs. Serogroup B remains the predominant serogroup for IMD in NSW and now accounts for 80% of cases. Research is underway to develop a vaccine for serogroup B disease, 16 which would substantially reduce the burden of IMD in Australia and worldwide. Although the proportion of annual IMD notifications due to serogroup B disease has increased over time, the actual number of serogroup B notifications has declined since 2000. This decrease is not likely to be related to the meningococcal C vaccination program but may reflect a natural drift in the virulence of meningococcal B strains in the community. 6 Notifications for serogroups Y and W135 have remained low and stable.
Although notifications for IMD have reduced greatly, reducing deaths and disability remain key challenges in the management of IMD. IMD remains one of the leading infectious causes of death in children in Australia. Moreover, overseas studies indicate that 9% of children who survive IMD are left with major physical, cognitive and/or psychological disabilities, 17 and 50% of survivors of adolescent IMD experience major long-term sequelae including skin scarring, mobility difficulty, and speech and hearing problems. 18 Structured review of the management of individual IMD cases has been used to identify areas for improvement in the medical, laboratory and public health management of IMD cases 19 and has the potential to improve outcomes for people with IMD.
Conclusion
This study used routinely collected surveillance data to describe the epidemiology of IMD in NSW, and to examine trends in relation to the introduction of the meningococcal C vaccination program. The incidence of meningococcal C has decreased substantially since the introduction of the meningococcal C vaccination program. A key challenge for reducing the burden of IMD is to control serogroup B disease.
